Goldman Sachs Group Inc. Acquires 114,736 Shares of Novartis AG (NYSE:NVS)

Goldman Sachs Group Inc. grew its holdings in shares of Novartis AG (NYSE:NVSGet Rating) by 5.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,187,402 shares of the company’s stock after buying an additional 114,736 shares during the period. Goldman Sachs Group Inc. owned 0.10% of Novartis worth $191,331,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Fisher Asset Management LLC boosted its holdings in shares of Novartis by 0.8% during the 4th quarter. Fisher Asset Management LLC now owns 10,384,666 shares of the company’s stock valued at $908,347,000 after buying an additional 79,637 shares in the last quarter. Boston Partners boosted its holdings in shares of Novartis by 6.7% during the 4th quarter. Boston Partners now owns 4,677,403 shares of the company’s stock valued at $409,194,000 after buying an additional 292,854 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Novartis by 21.5% during the 3rd quarter. Wellington Management Group LLP now owns 4,214,932 shares of the company’s stock valued at $344,696,000 after buying an additional 745,157 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Novartis by 2.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,205,694 shares of the company’s stock valued at $367,871,000 after buying an additional 89,226 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Novartis by 35.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,870,136 shares of the company’s stock valued at $338,521,000 after buying an additional 1,003,235 shares in the last quarter. Hedge funds and other institutional investors own 9.40% of the company’s stock.

NVS has been the subject of several recent analyst reports. Credit Suisse Group lifted their price target on Novartis from CHF 85 to CHF 88 in a research report on Thursday, April 28th. StockNews.com initiated coverage on Novartis in a research report on Thursday, March 31st. They issued a “strong-buy” rating for the company. Societe Generale lowered their price target on Novartis from CHF 107 to CHF 105 in a research report on Thursday, February 3rd. Zacks Investment Research lowered Novartis from a “hold” rating to a “sell” rating and set a $94.00 price target for the company. in a research report on Friday, April 22nd. Finally, Wolfe Research lowered Novartis from an “outperform” rating to a “market perform” rating in a research report on Monday, May 9th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Novartis presently has a consensus rating of “Hold” and an average price target of $90.50.

Shares of Novartis stock traded up $0.44 during trading hours on Friday, reaching $85.82. 2,519,380 shares of the stock traded hands, compared to its average volume of 2,351,205. The company has a 50 day moving average price of $87.69 and a 200 day moving average price of $85.99. The firm has a market capitalization of $191.96 billion, a price-to-earnings ratio of 7.99, a P/E/G ratio of 2.45 and a beta of 0.52. Novartis AG has a one year low of $79.09 and a one year high of $95.17. The company has a quick ratio of 1.01, a current ratio of 1.25 and a debt-to-equity ratio of 0.37.

Novartis (NYSE:NVSGet Rating) last released its quarterly earnings results on Tuesday, April 26th. The company reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.44 by $0.02. The business had revenue of $12.53 billion during the quarter, compared to the consensus estimate of $12.61 billion. Novartis had a return on equity of 23.16% and a net margin of 46.47%. The business’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.52 EPS. Sell-side analysts anticipate that Novartis AG will post 6.07 earnings per share for the current year.

Novartis Company Profile (Get Rating)

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.

Featured Articles

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVSGet Rating).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.